Predicting successful biologics tapering in patients with inflammatory arthri-tis: Secondary analyses based on the BIODOPT trial
Journal article
Uhrenholt L. et al, (2023), British journal of clinical pharmacology
Efficacy of certolizumab pegol across baseline rheumatoid factor subgroups in patients with rheumatoid arthritis: Post-hoc analysis of clinical trials.
Journal article
Tanaka Y. et al, (2023), Int j rheum dis
Et tu, Brutinib? Demise of a kinase target in rheumatoid arthritis?
Journal article
TAYLOR PC., (2023), Lancet rheumatology
Pain in the joints and beyond; the challenge of rheumatoid arthritis
Journal article
TAYLOR P., (2023), Lancet rheumatology
Disease activity-guided tapering of biologics in patients with inflammatory arthritis: a pragmatic, randomized, open-label, equivalence trial.
Journal article
Uhrenholt L. et al, (2023), Scand j rheumatol, 1 - 12
Approaches to optimising access to NICE-approved biologic anti-TNFs for patients with rheumatoid arthritis with moderately active disease
Journal article
TAYLOR PC. et al, (2023), Bmc medicine
Baricitinib safety for events of special interest in populations at risk: analysis from randomised trial data across rheumatologic and dermatologic indications
Journal article
TAYLOR PC. et al, (2023), Advances in therapy
Patient Disease Trajectories in Rheumatoid Arthritis Patients Treated with Baricitinib 4-mg in 4 Phase 3 Clinical Studies
Journal article
TAYLOR PC. et al, (2023), Rheumatology and therapy
Pathogenesis of chronic chikungunya arthritis: resemblances and links with rheumatoid arthritis
Journal article
Amaral JK. et al, (2022), Travel medicine and infectious disease
Outcomes following Adalimumab bio-originator to biosimilar switch - a comparison using real-world patient and physician reported data in European countries
Journal article
TAYLOR PC. et al, (2022), Rheumatology and therapy
A Review of Safety Outcomes from Clinical Trials of Baricitinib in Rheumatology, Dermatology and COVID-19
Journal article
Bieber T. et al, (2022), Advances in therapy
Impact of initial therapy with upadacitinib or adalimumab on achievement of 48-week treatment goals in patients with rheumatoid arthritis: post hoc analysis of SELECT-COMPARE
Journal article
Mysler E. et al, (2022), Rheumatology
Rituximab versus tocilizumab and B-cell status in TNF-alpha inadequate-responder rheumatoid arthritis patients: the R4-RA RCT
Journal article
Humby F. et al, (2022)
The effect of tofacitinib on residual pain in patients with rheumatoid arthritis and psoriatic arthritis
Journal article
Dougados M. et al, (2022), Rmd open
The opportunities and challenges of telemedicine in the management of people with rheumatoid arthritis
Journal article
TAYLOR P., (2022), Journal of rheumatology
Managing inadequate response to initial anti-TNF therapy in rheumatoid arthritis: optimising treatment outcomes
Journal article
TAYLOR P. et al, (2022), Therapeutic advances in musculoskeletal disease
Assessing the Relationship of Patient Global Assessment of Disease Activity and Health Related Quality of Life by SF-36 with Other Patient-Reported Outcomes in Rheumatoid Arthritis: Post Hoc Analyses of Data from Phase 3 Trials of Baricitinib
Conference paper
Strand V. et al, (2022), Journal of rheumatology, 49, 833 - 834
Safety Profile of Baricitinib for the Treatment of Rheumatoid Arthritis Up to 9.3 Years: An Updated Integrated Safety Analysis
Conference paper
Taylor P. et al, (2022), Journal of rheumatology, 49, 832 - 832
Rituximab versus tocilizumab in rheumatoid arthritis: synovial biopsy-based biomarker analysis of the phase 4 R4RA randomized trial
Journal article
Rivellese F. et al, (2022), Nature medicine